secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0000950170-22-005040
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.
- Collaboration revenue $1.3M for FY 2021 from Genmab R&D collaboration (vs $0.2M in 2020).
- R&D expenses $75.7M, G&A $18.4M; operating loss $92.8M for FY 2021.
- BDC-1001 (HER2) Phase 1/2 on track for recommended Phase 2 dose in 2022; Opdivo combo arm dosed first patient Dec 2021.
- Preclinical data on BDC-2034, BDC-3042, and PD-L1 ISAC to be presented at AACR 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/0000950170-22-005040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/bolt-20220330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer